Grifols (ADR) (GRFS)
Builds plasma-derived therapies, diagnostics, and biologic supplies around an integrated plasma network.
Something off on this page? Send us feedback.
Plasma collection supplies an integrated Biopharma chain of human-plasma therapies, while Diagnostic offers testing equipment and reagents. International operations include Bio Supplies, which offers non-therapeutic biological products and third-party plasma sales.
Plasma collection feeds an integrated Biopharma chain that fractionates human plasma and commercializes plasma-derived therapies. Diagnostic provides testing equipment and reagents, while Bio Supplies offers non-therapeutic biological products and third-party plasma sales.
Operations expanded from Spain through acquisitions in Europe and the United States, with activity also spanning Latin America, Africa, and Asia. Plasma Procurement, Biopharma, Diagnostic, Bio Supplies, and Others form the internal business structure; Plasma Procurement supplies Biopharma and produces no external revenue.
The model relies on plasma collection, complex fractionation and manufacturing, and regulated therapeutic and diagnostic markets.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $605.3M · Total debt $9.74B · Total assets $22.99B · Shareholders' equity $6.35B
- Revenue
- $2.14B
- Operating income
- $376.4M
- Net income
- $176.2M
Reported in EUR, converted at the latest exchange rate
HistoryDividendAnnual yield
| Institutions | 33.75% | 285.56M ADS | |
|---|---|---|---|
| 172 holders · as of Jun 30, 2026 | |||
| Other | 66.25% | 560.42M ADS | |
| remainder | |||
845.97M ADS as of Sep 2, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Brandes Investment Partners, LPInstitution | 8.94% | 37.82M ADS · 37.82M ADS | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 5.42% | 22.91M ADS · 22.91M ADS | as of Jun 30, 2026 |
Permian Investment Partners, LPInstitution | 4.67% | 19.74M ADS · 19.74M ADS | as of Jun 30, 2026 |
Black Creek Investment Management Inc.Institution | 1.82% | 7.68M ADS · 7.68M ADS | as of Jun 30, 2026 |
Bank of America Corp /DE/Institution | 1.55% | 6.55M ADS · 6.55M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Takeda (ADR)
Plasma-derived immunoglobulin and alpha-1 therapy overlap
- argenx (ADR)
Non-plasma CIDP treatment alternative to subcutaneous immunoglobulin
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Grifols (ADR) | $7.42 | +0.82% | $6.23B | 9.6 | — | 0.7 | −1.8% |
| Takeda (ADR) | $19.03 | +0.71% | $60.11B | 52.5 | 60.1 | 2.0 | +4.2% |
| argenx (ADR) | $976.92 | −1.14% | $61.45B | 37.7 | — | 10.2 | +197.0% |
| Median | 45.1 | 60.1 | 6.1 | +100.6% |